Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Harrow Health Inc (HROW)
NASDAQ:HROW
Harrow Health (HROW) Stock Price & Analysis
260 Followers
HROW Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.60 - $24.19
Previous Close$16.16
Volume513.00K
Average Volume (3M)519.49K
Market Cap
$571.77M
Enterprise Value$687.24M
Total Cash (Recent Filing)$73.88M
Total Debt (Recent Filing)$189.71M
Price to Earnings (P/E)-17.8
Beta0.72
Next Earnings
Aug 06, 2024EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding35,382
10 Day Avg. Volume753,667
30 Day Avg. Volume519,492
Standard Deviation0.19
R-Squared0.03
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)-0.01
Price to Sales (P/S)0.00600
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.33
Enterprise Value/Gross Profit10.87
Enterprise Value/Ebitda54.94
Forecast
1Y Price Target
$25.00Price Target Upside54.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Harrow Health News
Bulls Say, Bears Say
Bulls Say
Commercial Success And Market ResponseVEVYE prescription volume's continued growth since its market introduction suggests a robust market response, positioning it as a potential leader in the chronic dry eye disease market.
Company Financial Health And GrowthWith Harrow Health's positive sales performance outlook, strategic transactions, and increasing prescription sales, there is a clear trajectory for accelerated revenue and earnings growth.
Product Growth And Market PenetrationIHEEZO and VEVYE show strong signs of market penetration with secured supply agreements, indicating potential for significant sales growth.
Bears Say
Financial PerformanceOperating expenses were above forecast, leading to a substantial shortfall in AEBITDA.
Market Expectations3Q results missed estimates on both top and bottom-line while also guiding down 4Q/2024E outlook.
Product DevelopmentTRIESCENCE related delay in manufacturing removes a key near-term growth driver.
---
Ownership Overview
22.42% Insiders
14.84% Mutual Funds
39.08% Other Institutional Investors
23.66% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HROW FAQ
What was Harrow Health Inc’s price range in the past 12 months?
Harrow Health Inc lowest stock price was $7.60 and its highest was $24.19 in the past 12 months.
What is Harrow Health Inc’s market cap?
Currently, no data Available
When is Harrow Health Inc’s upcoming earnings report date?
Harrow Health Inc’s upcoming earnings report date is Aug 06, 2024 which is in 81 days.
How were Harrow Health Inc’s earnings last quarter?
Harrow Health Inc released its earnings results on May 13, 2024. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.218 by -$0.162.
Is Harrow Health Inc overvalued?
According to Wall Street analysts Harrow Health Inc’s price is currently Undervalued.
Does Harrow Health Inc pay dividends?
Harrow Health Inc does not currently pay dividends.
What is Harrow Health Inc’s EPS estimate?
Harrow Health Inc’s EPS estimate is -$0.21.
How many shares outstanding does Harrow Health Inc have?
Harrow Health Inc has 35,381,610 shares outstanding.
What happened to Harrow Health Inc’s price movement after its last earnings report?
Harrow Health Inc reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.218. Following the earnings report the stock price went up 34.548%.
Which hedge fund is a major shareholder of Harrow Health Inc?
Among the largest hedge funds holding Harrow Health Inc’s share is Private Capital Management, LLC. It holds Harrow Health Inc’s shares valued at 31M.
---
Harrow Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.00 (54.70% Upside)
$25.00 (54.70% Upside)
Blogger Sentiment
Bullish
HROW Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 582.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.19%
12-Months-Change
Fundamentals
Return on Equity
-76.44%
Trailing 12-Months
Asset Growth
35.66%
Trailing 12-Months
Company Description
Harrow Health Inc
Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits.
---
HROW Company Deck
---
HROW Earnings Call
Q1 2024
0:00 / 0:00
---
HROW Stock 12 Month Forecast
Average Price Target
$25.00
▲(54.70% Upside)
Technical Analysis
Avid Bioservices
―
Fennec Pharmaceuticals
―
Intra-Cellular Therapies
―
Kala Pharmaceuticals
―
Best Analysts Covering HROW
1 Year
1 Year Success Rate
6/9 ratings generated profit
1 Year Average Return
+23.87%
reiterated a buy rating 3 days ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +23.87% per trade.
---